Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991616 | 0.85 | SMYD2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL29069543 | 0.85 | SMYD2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL29991050 | 0.85 | SMYD2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL25256069 | 0.84 | SMYD2 (0.33) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL25302001 | 0.84 | SMYD2 (0.33) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL27039633 | 0.84 | SMYD2 (0.38) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL25294460 | 0.83 | SMYD2 (0.35) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL25427580 | 0.83 | SMYD2 (0.35) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL2914349 | 0.83 | RIPK1 (0.41) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 | |
| SCHEMBL27166466 | 0.83 | SMYD2 (0.34) | SMYD2SMN1; SMN2CYP3A4HTTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211123-B1 | ANTITUMORAL ASCORBIC ACID ESTERS | SUIGENERIS FARM S L (ES) | 2024-11-06 | — | — | EP | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20230278974-A1 | ANTITUMORAL ASCORBIC ACID ESTERS | SUIGENERIS FARMACOSMETICS, S.L. (ES) | 2023-09-07 | — | — | US | disclosed |
| US-20230278974-A1 | ANTITUMORAL ASCORBIC ACID ESTERS | SUIGENERIS FARMACOSMETICS, S.L. (ES) | 2023-09-07 | — | — | US | disclosed |
| EP-4211123-A1 | ANTITUMORAL ASCORBIC ACID ESTERS | Suigeneris Farmacosmetics, S.L. (ES) | 2023-07-19 | — | — | EP | disclosed |
| EP-3967684-A1 | ANTITUMORAL ASCORBIC ACID ESTERS | Suigeneris Farmacosmetics, S.L. (ES) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278974-A1 | ANTITUMORAL ASCORBIC ACID ESTERS | RNASE1, AKR1C3, CYP27A1 | SMYD2 4757/4885SMN1; SMN2 404/4885CYP3A4 1431/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | SMYD2 3312/4885SMN1; SMN2 2737/4885CYP3A4 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.